BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The first TKI, imatinib (a BCR–ABL TKI), was approved by the United States Food and Drug Administration (US FDA) in May 2001 for the treatment of chronic myeloid leukemia (CML).